Vg Life Sciences Inc
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is … Read more
Vg Life Sciences Inc (VGLS) - Net Assets
Latest net assets as of September 2015: $-4.34 Million USD
Based on the latest financial reports, Vg Life Sciences Inc (VGLS) has net assets worth $-4.34 Million USD as of September 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.12 Million) and total liabilities ($5.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.34 Million |
| % of Total Assets | -388.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -241.02% |
| Growth Volatility | 151.98 |
Vg Life Sciences Inc - Net Assets Trend (1999–2014)
This chart illustrates how Vg Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vg Life Sciences Inc (1999–2014)
The table below shows the annual net assets of Vg Life Sciences Inc from 1999 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-12-31 | $-4.51 Million | -0.84% |
| 2013-12-31 | $-4.47 Million | -106365.39% |
| 2012-12-31 | $-4.20K | +99.59% |
| 2011-12-31 | $-1.01 Million | +49.59% |
| 2010-12-31 | $-2.01 Million | -1017.78% |
| 2009-12-31 | $-180.00K | +96.12% |
| 2008-12-31 | $-4.64 Million | +0.24% |
| 2007-12-31 | $-4.65 Million | +36.45% |
| 2006-12-31 | $-7.32 Million | -329.20% |
| 2005-12-31 | $3.20 Million | -25.23% |
| 2004-12-31 | $4.27 Million | +195.90% |
| 2003-12-31 | $-4.46 Million | -5.01% |
| 2002-12-31 | $-4.24 Million | -3.38% |
| 2001-12-31 | $-4.10 Million | -1934.20% |
| 2000-12-31 | $-201.79K | -105.91% |
| 1999-12-31 | $-98.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vg Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11666553500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.75 Million | % |
| Other Comprehensive Income | $-1.75 Million | % |
| Other Components | $112.31 Million | % |
| Total Equity | $-4.62 Million | 100.00% |
Vg Life Sciences Inc Competitors by Market Cap
The table below lists competitors of Vg Life Sciences Inc ranked by their market capitalization.
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vg Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -5,464,385 to -4,617,125, a change of 847,260.
- Net income of 2,115,108 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,467,754.
- Other factors increased equity by 199,906.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.12 Million | +45.81% |
| Other Comprehensive Income | $-1.47 Million | -31.79% |
| Other Changes | $199.91K | +4.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Vg Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-15.06 | $0.00 | x |
| 2001-12-31 | $-0.08 | $0.00 | x |
| 2002-12-31 | $-0.07 | $0.00 | x |
| 2003-12-31 | $-0.06 | $0.00 | x |
| 2004-12-31 | $0.04 | $0.00 | x |
| 2005-12-31 | $0.02 | $0.00 | x |
| 2006-12-31 | $-0.04 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $-0.63 | $0.00 | x |
| 2014-12-31 | $-0.19 | $0.00 | x |
| 2019-12-31 | $-0.06 | $0.00 | x |
| 2020-12-31 | $-0.06 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vg Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-19.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-143.55K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-945.64K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.35 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.00 Million |
| 2004 | -148.94% | 0.00% | 0.00x | 1.59x | $-6.79 Million |
| 2005 | -147.43% | 0.00% | 0.00x | 1.99x | $-5.03 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.11 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.31 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.36K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.98 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.43 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $553.00K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-528.71K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-693.91K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $2.58 Million |
Industry Comparison
This section compares Vg Life Sciences Inc's net assets metrics with peer companies in the Real Estate - Development industry.
Industry Context
- Industry: Real Estate - Development
- Average net assets among peers: $8,708,016,178
- Average return on equity (ROE) among peers: -18.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vg Life Sciences Inc (VGLS) | $-4.34 Million | 0.00% | N/A | $0.95 |
| Applied Development Holdings Limited (ADHLF) | $872.99 Million | -18.66% | 0.65x | $1.95 Million |
| Alset Ehome International Inc (AEI) | $29.20 Million | -17.09% | 0.67x | $7.53 Million |
| Autris (AUTR) | $-56.91K | 0.00% | 0.00x | $1.57K |
| AMREP Corporation (AXR) | $127.47 Million | 9.98% | 0.05x | $80.48 Million |
| Ayala Land Inc (AYAAF) | $50.75 Billion | 8.64% | 0.64x | $3.06 Billion |
| Bayport International Holdings Inc (BAYP) | $124.43K | -208.38% | 2.27x | $1.00 |
| Beijing North Star Company Limited (BEIJF) | $8.81 Billion | 5.10% | 1.91x | $161.03 Million |
| China Overseas Land Investment (CAOVY) | $25.08 Billion | 15.75% | 1.41x | $20.11 Billion |
| C C Land Holdings Limited (CCLHF) | $354.40 Million | 7.00% | 0.52x | $141.49 Million |
| Century Communities Inc (CCS) | $1.06 Billion | 10.64% | 1.35x | $1.45 Billion |